SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Investors are actively debating the long-term potential of the 4CHAN token, positioning it as a foundational "index fund" of meme culture with significant upside should it capture broader adoption. While some community members remain skeptical of volatility and price action, proponents emphasize the token's cultural roots, low market capitalization, and historical significance as catalysts for a potential major rally.

Patterson-UTI Energy, Inc. engages in the provision of drilling and pressure pumping services, directional drilling, rental equipment, and technology. It operates through the following segments: Drilling Services, Completion Services, and Drilling Products. The Drilling Services segment represents contract drilling, directional drilling, oilfield technology, and electrical controls and automation businesses. The Completion Services segment offers hydraulic fracturing, wireline and pumping, completion support, cementing, and pressure pumping business. The Drilling Products segment focuses on manufacturing and distribution of drill bits business. The company was founded by Cloyce A. Talbott and A. Glenn Patterson in 1978 and is headquartered in Houston, TX.

Patterson-UTI Energy Inc

Patterson-UTI Energy is trending as investors monitor the company's international expansion into Argentina's Vaca Muerta region and the ongoing industry-wide focus on drilling efficiency. The community is actively discussing its leverage to energy prices, with many debating whether the current stock valuation offers a compelling entry point for long-term exposure to U.S. land drilling and production.

D.R. Horton, Inc. engages in the construction and sale of single-family housing. It operates through the following geographical segments: Northwest, Southwest, South Central, Southeast, East, and North. The Northwest segment relates to Colorado, Oregon, Utah, and Washington. The Southwest segment covers Arizona, California, Hawaii, Nevada, and New Mexico. The South Central segment is involved in Arkansas, Oklahoma, and Texas. The Southeast segment refers to Alabama, Florida, Louisiana, and Mississippi. The East segment operates Georgia, North Carolina, South Carolina, and Tennessee. The North segment focuses on Delaware, Illinois, Indiana, Iowa, Kentucky, Maryland, Minnesota, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia. The company was founded by Donald Ray Horton in 1978 and is headquartered in Arlington, TX.

D.R. Horton Inc.

D.R. Horton is currently experiencing significant downward pressure as investors react to concerns over housing affordability, rising mortgage rates, and potential antitrust scrutiny from the Justice Department. The community remains deeply divided, with some traders betting on further downside while others monitor for a turnaround driven by potential rate cuts or technical rebounds from oversold levels.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as investors aggressively accumulate shares ahead of a series of pivotal Phase 3 data readouts expected throughout 2026, which the community views as a potential make-or-break moment for the company's retinal disease pipeline. While the stock has seen significant volatility, sentiment is currently driven by institutional interest and bullish technical setups, with many participants actively debating whether the company's recent pipeline de-risking and cash runway are sufficient to fuel a long-term recovery to previous valuation levels.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

Investors are closely monitoring the technology sector for potential exhaustion as XLK shows signs of cooling momentum after a historic streak of consecutive gains. While AI infrastructure demand continues to fuel bullish sentiment in mega-cap tech, the community is actively debating whether current valuation levels are sustainable or if the sector is prone to a technical pullback.

Global X Funds - Global X Silver Miners ETF

Global X Silver Miners ETF (SIL) is drawing significant attention as investors position for an ongoing structural deficit in silver supply against robust industrial demand. The community is actively discussing the divergence between spot price strength and the mining equities, with many traders viewing the current volatility and sector-wide shakeouts as a high-reward opportunity to accumulate positions ahead of potential long-term upside.

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic Plc

Medtronic is capturing market attention following a fiscal third-quarter earnings report that surpassed analyst expectations on both earnings and revenue, despite initial share price volatility tied to cautious full-year guidance and tariff-related impacts. The community is actively debating the company's long-term value, with active discussions focusing on its dividend reliability, potential for M&A-driven growth in cardiovascular and diabetes segments, and the impact of the upcoming MiniMed spinoff.

Anglogold Ashanti Plc is a holding company, which engages in the operation and exploration of gold mining projects through its subsidiary. Its asset portfolio includes production from Argentina, Australia, Brazil, the Democratic Republic of Congo, Ghana, Guinea, and Tanzania. The firm also produces silver and sulfuric acid as by-products. The company was founded in 1998, and is headquartered in Staines-upon-Thames, the United Kingdom.

AngloGold Ashanti Plc.

AngloGold Ashanti Ltd.

AngloGold Ashanti is trending as investors weigh its aggressive exploration and production expansion, including the strategic acquisition of Augusta Gold, against broader macroeconomic concerns about gold's price volatility and operational cost pressures. The community remains deeply divided, with some analysts and long-term investors highlighting the stock's role as a dividend-paying hedge against inflation, while others express frustration over recent price corrections and technical weakness.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Toronto, Canada.

Bank of Montreal - MicroSectors Gold Miners -3X Inverse Leveraged ETNs

The $GDXD ETN is experiencing extreme volatility as traders aggressively bet on a gold market reversal, fueling intense debate over whether current precious metal valuations are sustainable or nearing an inevitable pullback. Community members are actively sharing their experiences with high-stakes swing trading and hedging strategies, emphasizing the risks and potential rewards inherent in the fund's inverse leveraged structure.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate the impact of new ETF launches and institutional adoption on its long-term viability, while community sentiment remains sharply divided between those aggressively accumulating at current price levels and those frustrated by persistent downward pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAB Biotherapeutics (SABS) to Release Earnings on Friday

SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling...

Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS

Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the...

SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered SAB Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00

Chardan Capital boosted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday...

SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright

HC Wainwright reduced their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday...

SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf

SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer's 36th Annual Healthcare Life Sciences Conference to outline its strategy in type 1 diabetes (T1D), emphasizing development of a...

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Analysts

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. One...

Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 24.7%

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling...

SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026

SAB Biotherapeutics (NASDAQ:SABS) used a presentation at Guggenheim's Emerging Outlook Biotech Summit 2026 to outline its strategy in type 1 diabetes (T1D), focusing on a pivotal Phase 2b program for...

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.21	--	--	N/A
Q4 '25	-$0.22	--	--	N/A
Q3 '25	$0.23	-$0.21	-192.11%	MISSED
Q2 '25	-$1.09	-$1.09	0.18%	BEAT
Q1 '25	-$0.56	--	--	N/A

SABS
SAB Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SABS News

SABSSAB Biotherapeutics Inc